Osteosarcoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Osteosarcoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Denosumab with Chemotherapy (Cisplatin, Methotrexate, Doxorubicin) for Patients with Metastatic Osteosarcoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-denosumab-with-chemotherapy-cisplatin-methotrexate-doxorubicin-for-patients-with-metastatic-osteosarcoma/ Wed, 29 Apr 2026 15:03:02 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-denosumab-with-chemotherapy-cisplatin-methotrexate-doxorubicin-for-patients-with-metastatic-osteosarcoma/ This clinical trial is focused on studying the treatment of metastatic osteosarcoma, a type of bone cancer that has spread to other parts of the body. The study will explore the effectiveness of a medication called denosumab when used in combination with standard chemotherapy drugs. The chemotherapy regimen includes cisplatin, methotrexate, and doxorubicin hydrochloride. These medications are commonly used to treat various types of cancer and are administered through intravenous infusion or injection.

The purpose of this study is to evaluate how well the combination of denosumab and standard chemotherapy works in treating patients with metastatic osteosarcoma. Participants in the study will be randomly assigned to receive either the standard chemotherapy regimen alone or the standard chemotherapy regimen combined with denosumab. The study will be conducted over a period of time, with regular monitoring to assess the treatment’s effectiveness and any side effects experienced by the participants.

The trial aims to determine if the addition of denosumab can improve outcomes for patients with metastatic osteosarcoma. The primary focus is on measuring the 5-year event-free survival, which refers to the time patients remain free from cancer progression or recurrence. This study is an important step in finding more effective treatments for this aggressive form of cancer.

]]> Study on the Effectiveness and Safety of Regorafenib for Patients with Resistant Primary Bone Tumors https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-resistant-primary-bone-tumors/ Wed, 29 Apr 2026 15:00:58 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-resistant-primary-bone-tumors/ This clinical trial is focused on studying the effects of a medication called Regorafenib on patients with a type of cancer known as refractory primary bone tumors. These tumors are a form of cancer that originates in the bones and have not responded to previous treatments. The purpose of the study is to evaluate how effective and safe Regorafenib is for these patients.

Participants in the study will take Regorafenib in the form of a film-coated tablet, which is taken orally. The study will monitor patients over a period to see how the medication affects their condition. This includes observing any changes in the tumor, as well as any side effects that may occur. The study aims to determine if Regorafenib can help control the disease and improve the quality of life for patients.

Throughout the study, various health checks will be conducted, such as laboratory tests and heart monitoring, to ensure the safety of the participants. The study will also look at how the body processes the medication, including how long it takes to reach a steady level in the bloodstream. This information will help researchers understand the best way to use Regorafenib in treating refractory primary bone tumors.

]]> Study on the Effectiveness and Safety of Regorafenib for Patients with Metastatic Bone Sarcomas https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-metastatic-bone-sarcomas/ Wed, 29 Apr 2026 15:00:51 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-metastatic-bone-sarcomas/ This clinical trial is focused on studying the effects of a medication called regorafenib in patients with a type of cancer known as metastatic bone sarcoma. Metastatic bone sarcoma is a cancer that starts in the bones and can spread to other parts of the body. The purpose of the study is to evaluate how well regorafenib works in treating this condition and to assess its safety for patients.

Participants in the study will receive either regorafenib or a placebo, which is a substance with no active medication. The study will take place over several months, during which patients will be monitored regularly to see how their cancer responds to the treatment. This will involve various assessments, including imaging tests like MRI or CT scans, to track changes in the cancer. The study aims to determine if regorafenib can help control the cancer and improve the patients’ quality of life.

Throughout the study, patients will be closely observed for any side effects or changes in their condition. The information gathered will help researchers understand the potential benefits and risks of using regorafenib for treating metastatic bone sarcoma. This research is important for developing new treatment options for patients with this challenging type of cancer.

]]> Study on the Safety and Tumor-Fighting Effects of OMO-103 for Patients with Advanced Osteosarcoma https://clinicaltrials.eu/trial/study-on-the-safety-and-tumor-fighting-effects-of-omo-103-for-patients-with-advanced-osteosarcoma/ Wed, 29 Apr 2026 14:59:09 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-tumor-fighting-effects-of-omo-103-for-patients-with-advanced-osteosarcoma/ This clinical trial is focused on studying a type of cancer called Advanced High-Grade Osteosarcoma, which is a severe form of bone cancer. The treatment being tested in this study is a medication known as Omomyc, with the code name OMO-103. This medication is given to patients through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate the safety and effectiveness of Omomyc in treating this type of cancer.

Participants in the study will receive the medication over a period of time, and their health will be monitored closely to see how the cancer responds to the treatment. The study aims to understand how well Omomyc can stop or slow down the growth of the cancer. Patients will undergo regular check-ups, which may include imaging tests like MRI or CT scans, to track the progress of the treatment. The study will also look at how the treatment affects the overall quality of life of the participants.

Throughout the study, researchers will collect information on any side effects experienced by the participants to ensure the treatment is safe. The study will last for several months, and the results will help determine if Omomyc is a viable treatment option for patients with advanced high-grade osteosarcoma. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Omomyc against no treatment. The findings from this study could provide valuable insights into new ways to treat this challenging form of cancer.

]]> Study on Mifamurtide with Chemotherapy for Patients with High-Risk Osteosarcoma https://clinicaltrials.eu/trial/study-on-mifamurtide-with-chemotherapy-for-patients-with-high-risk-osteosarcoma/ Wed, 29 Apr 2026 14:27:29 +0000 https://clinicaltrials.eu/trial/study-on-mifamurtide-with-chemotherapy-for-patients-with-high-risk-osteosarcoma/ This clinical trial is focused on studying a type of bone cancer called osteosarcoma, which is considered high-risk. High-risk osteosarcoma can either be metastatic, meaning it has spread to other parts of the body at the time of diagnosis, or it can be localized but shows a poor response to initial treatment. The study is evaluating the effectiveness of a medication called mifamurtide, also known by its code name MEPACT, when used in combination with standard chemotherapy treatments. The chemotherapy medications involved in this study include doxorubicin hydrochloride, ifosfamide, cisplatin, methotrexate, and etoposide.

The purpose of the study is to determine if adding mifamurtide to the usual chemotherapy regimen can improve the outcomes for patients with high-risk osteosarcoma. Participants in the study will receive either the standard chemotherapy alone or the standard chemotherapy combined with mifamurtide. The treatment will be administered over a period of several weeks, and the effects will be monitored to see if the combination helps in preventing the cancer from returning or spreading.

Throughout the study, participants will be closely observed to track their progress and any side effects they may experience. The study aims to provide valuable information on whether the addition of mifamurtide can enhance the effectiveness of chemotherapy in treating high-risk osteosarcoma, potentially leading to better survival rates and outcomes for patients. The trial will continue until the estimated end date in 2033, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatment.

]]>